Autonomix medical, inc. engages leading medical experts to guide u.s. clinical and regulatory path in pancreatic cancer pain

Company on track to commence u.s. clinical studies in 2025 to support a de novo application for fda approval the woodlands, tx, april 08, 2025 (globe newswire) -- autonomix medical, inc. (nasdaq: amix) (“autonomix” or the “company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced it has engaged u.s. and international-based medical experts in interventional radiology and cancer pain to guide the company's u.s. clinical and regulatory path to ensure pre-clinical and clinical studies meet the needs of the company's expected fda de novo submission in 2026. the company's medical advisors include former society of interventional radiology past presidents, dr. michael brunner and dr. katharine krol of health tech guidance, dr. patricio polanco of ut southwestern and dr. nikola cesarovic of eth zÜrich.
AMIX Ratings Summary
AMIX Quant Ranking